Anlai Wang

发表

Identification of a regulatory autophosphorylation site in the serine-threonine kinase RIP2.

Chafen Lu, K. Clauser, T. Ocain, 2006, Cellular signalling.

Discovery of INCB3284, a Potent, Selective, and Orally Bioavailable hCCR2 Antagonist.

P. Scherle, K. Vaddi, M. Covington, 2011, ACS medicinal chemistry letters.

Discovery of NVP‐LEQ506, a Second‐Generation Inhibitor of Smoothened

John Green, J. Williams, B. Lagu, 2013, ChemMedChem.

Evaluation of Preclinical Activity of Isatuximab in Patients with Acute Lymphoblastic Leukemia

C. Nicolazzi, F. Adrián, J. Fromm, 2021, Molecular Cancer Therapeutics.

Discovery and Pharmacological Characterization of a Novel Rodent-Active CCR2 Antagonist, INCB3344

P. Scherle, F. Baribaud, L. Leffet, 2005, The Journal of Immunology.

Discovery of INCB9471, a Potent, Selective, and Orally Bioavailable CCR5 Antagonist with Potent Anti-HIV-1 Activity.

P. Scherle, K. Vaddi, Joseph Glenn, 2010, ACS medicinal chemistry letters.

Discovery of N-substituted 7-azaindoles as Pan-PIM kinases inhibitors - Lead optimization - Part III.

M. Levit, John Jiang, C. Barberis, 2019, Bioorganic & medicinal chemistry letters.

Discovery of N-substituted 7-azaindoles as Pan-PIM kinase inhibitors - Lead series identification - Part II.

Neil D. Moorcroft, M. Levit, C. Barberis, 2017, Bioorganic & medicinal chemistry letters.

Potent and Selective Biaryl Amide Inhibitors of Hematopoietic Progenitor Kinase 1 (HPK1).

M. Covington, S. Diamond, E. Behshad, 2022, ACS medicinal chemistry letters.

Discovery of Pyrazolopyridine Derivatives as HPK1 Inhibitors.

M. Covington, S. Diamond, E. Behshad, 2022, ACS medicinal chemistry letters.

Discovery of INCB3344, a potent, selective and orally bioavailable antagonist of human and murine CCR2.

P. Scherle, K. Vaddi, M. Covington, 2010, Bioorganic & medicinal chemistry letters.

Preparation of 7-Arylmethyl-1H-pyrrolo[3,4-c]pyridine-1,3-(2H)-diones and α-aryl-3-hydroxy-5-pyridylacetonitriles using arynic methodology

T. Holdeman, E. Biehl, Anlai Wang, 1998 .

The reaction of 2-chloro-4-nitrophenol and the isomeric chloronitrobenzenes with LDA under aryne-forming conditions

T. Holdeman, E. Biehl, Anlai Wang, 1998 .

A one-step synthesis of 1-substituted thieno[2,3-f]benzo[cd]indol-4-ones via benzyne-3-carboxylate

E. Biehl, Anlai Wang, 1998 .

The Reaction of 2-Chloro-4-nitrophenol and the Isomeric Chloronitrobenzenes with LDA under Aryne-Forming Conditions.

T. Holdeman, E. Biehl, Anlai Wang, 1999 .

Solvent Isotope Effect on the Complexation of Cyclodextrins in Aqueous Solutions

Y. Matsui, Anlai Wang, 1994 .

EFFECT OF ALPHA -CYCLODEXTRIN ON THE HYDRATION OF ALIPHATIC ALDEHYDES IN WATER

Y. Matsui, Anlai Wang, 1994 .

Discovery of INCB10820/PF-4178903, a potent, selective, and orally bioavailable dual CCR2 and CCR5 antagonist.

D. J. Rogier, P. Scherle, R. Devraj, 2011, Bioorganic & medicinal chemistry letters.

Discovery of INCB8761/PF-4136309, a Potent, Selective, and Orally Bioavailable CCR2 Antagonist.

Lixin Shao, Michael Xia, D. J. Rogier, 2011, ACS medicinal chemistry letters.

Pharmacological characterization of INCB3344, a small molecule antagonist of human CCR2.

R. Wynn, P. Scherle, F. Baribaud, 2009, Biochemical and biophysical research communications.

Discovery and Pharmacological Characterization of a Novel Rodent-Active CCR2 Antagonist, INCB3344

P. Scherle, F. Baribaud, T. Burn, 2005, The Journal of Immunology.

Interfering with Resistance to Smoothened Antagonists by Inhibition of the PI3K Pathway in Medulloblastoma

Jing Yuan, William R. Sellers, Christoph Lengauer, 2010, Science Translational Medicine.

PIM inhibitors target CD25-positive AML cells through concomitant suppression of STAT5 activation and degradation of MYC oncogene.

S. Gross, Q. Gao, D. Wiederschain, 2014, Blood.

suppression of STAT 5 activation and degradation of MYC oncogene PIM inhibitors target CD 25-positive AML cells through concomitant

S. Gross, Q. Gao, D. Wiederschain, 2014 .

Combination of PIM and JAK2 inhibitors synergistically suppresses cell proliferation and overcomes drug resistance of myeloproliferative neoplasms

D. Wiederschain, C. García-echeverría, C. Lengauer, 2014, Oncotarget.

Evaluation of Cancer Dependence and Druggability of PRP4 Kinase Using Cellular, Biochemical, and Structural Approaches

Q. Gao, D. Wiederschain, C. García-echeverría, 2013, The Journal of Biological Chemistry.

Participation of Rip2 in Lipopolysaccharide Signaling Is Independent of Its Kinase Activity*

Chafen Lu, B. Jaffee, T. Ocain, 2005, Journal of Biological Chemistry.

Regulation of IRAK-4 kinase activity via autophosphorylation within its activation loop.

T. Parsons, Chafen Lu, B. Jaffee, 2007, Biochemical and biophysical research communications.

Nucleotide binding to CARD12 and its role in CARD12-mediated caspase-1 activation.

Chafen Lu, T. Ocain, Yajun Xu, 2005, Biochemical and biophysical research communications.

Discovery of SARxxxx92, a pan-PIM kinase Inhibitor, efficacious in a KG1 tumor model.

M. Levit, C. Barberis, Shih-Min A. Huang, 2020, Bioorganic & medicinal chemistry letters.

Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells

D. Wiederschain, M. Chiron, Y. Tai, 2020, Frontiers in Immunology.

Discovery of Orally Bioavailable FGFR2/FGFR3 Dual Inhibitors via Structure-Guided Scaffold Repurposing Approach.

April Horsey, L. Leffet, M. Covington, 2023, ACS medicinal chemistry letters.

Functional isolation and characterization of human hematopoietic stem cells.

D. Scadden, A. Berardi, J. Levine, 1995, Science.

Recombinant human interleukin-11 synergizes with steel factor and interleukin-3 to promote directly the early stages of murine megakaryocyte development in vitro.

S. Neben, K. Turner, Anlai Wang, 2000, Blood.

Cloning and characterization of HTK, a novel transmembrane tyrosine kinase of the EPH subfamily.

D. Goeddel, D. Scadden, J. Groopman, 1994, The Journal of biological chemistry.

Interfering with Resistance to Smoothened Antagonists by Inhibition of the PI3K Pathway in Medulloblastoma

Michael P. Morrissey, W. Sellers, J. Monahan, 2010, Science Translational Medicine.

Characterization of a Novel Rodent-Active Discovery and Pharmacological

P. Scherle, F. Baribaud, L. Leffet, 2013 .

Abstract 1632: Antibody mediated crosslinking of CD38 triggers costimulatory signaling and promotes T cell effector function

Mun Kyung Hwang, D. Wiederschain, Shujia Dai, 2021, Immunology.

Abstract B26: Immunomodulatory activity of Isatuximab

F. Adrián, Zhili Song, Anlai Wang, 2017 .

Discovery of INCB3344, a potent, selective and orally bioavailable antagonist of human and murine CCR2.

P. Scherle, K. Vaddi, M. Covington, 2010, Bioorganic & medicinal chemistry letters.